Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in Sao Paulo state

Imagem de Miniatura
Arquivos
art_MOREIRA_Prevalence_of_naturally_occurring_amino_acid_substitutions_associated_2018.PDF (1.87 MB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER WIEN
Autores
MOREIRA, Regina Celia
LEMOS, Marcilio Figueiredo
SANTANA, RAbia Anita Ferraz
DASTOLI, Gregorio Tadeu Fernando
CASTRO, Vanessa Fusco Duarte de
Citação
ARCHIVES OF VIROLOGY, v.163, n.10, p.2757-2764, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hepatitis C (HCV)-infected patients are treated with direct-acting antiviral agents (DAAs) in highly effective, well-tolerated, all-oral regimens. However, naturally occurring resistance-associated amino acid substitutions (RASs) may be selected during treatment. This study aimed to screen naturally occurring RASs NS3/NS4A inhibitors (PIs). Samples were obtained from DAA naive patients, living in Sao Paulo state, Brazil. Screening for RASs in the HCV NS3 region was conducted in 859 samples from HCV-infected patients, of which 425 and 434 samples were subtype la and lb, respectively. HCV-RNA was extracted, amplified, and sequenced. The overall prevalence of RASs to HCV PIs was 9.4%. The following RASs were observed in HCV-1a subtype infected patients: V36L (2.6%), T54S (1.6%), V55I/A (1.2% / 8.9%, respectively), Q80K (2.1%), R155K (0.5%), and D168E (0.2%); and in HCV-1b infected patients: V36L (0.7%), T54A/S (0.2% and 0.5%, respectively), V55A (0.5%), Q80K (0.2%), D168E (1.6%), and M175L (0.5%). HCV la infected subjects had higher serum viral load than that seen in patients infected with HCV 1b. There was no difference between the proportions of NS3 RASs with regards to geographic distribution within the investigated areas. These findings should be supported by additional studies in Brazil to help in the formation of local clinical guidelines for managing hepatitis C.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/29652
Referências
  1. AASLD, 2016, HEP C GUID AASLD IDS
  2. Amaku M, 2016, B MATH BIOL, V78, P970, DOI 10.1007/s11538-016-0170-4
  3. [Anonymous], 2017, GLOB HEP REP 2017
  4. Barnard RJO, 2013, VIROLOGY, V444, P329, DOI 10.1016/j.virol.2013.06.029
  5. Caiaffa WT, 1998, REV BRAS EPIDEMIOL, V1, P190, DOI [10.1590/S1415-790X1998000200009, DOI 10.1590/S1415-790X1998000200009]
  6. Cento V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039652
  7. Chen JY, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.17
  8. Coppola N, 2016, J MED VIROL, V88, P1659, DOI 10.1002/jmv.24527
  9. Fourati S, 2015, VIRUSES-BASEL, V7, P6346, DOI 10.3390/v7122941
  10. Gaspareto KV, 2016, ANTIVIR THER, V21, P653, DOI 10.3851/IMP3057
  11. Jensen SB, 2015, ANTIMICROB AGENTS CH, V59, P7426, DOI 10.1128/AAC.01953-15
  12. Kwo P, 2016, HEPATOLOGY, V64, P370, DOI 10.1002/hep.28467
  13. Lampe E, 2013, ANTIVIR THER, V18, P435, DOI 10.3851/IMP2606
  14. Lawitz E, 2017, HEPATOLOGY, V65, P1803, DOI 10.1002/hep.29130
  15. Lawitz E, 2013, ANTIVIR RES, V99, P214, DOI [10.1016/j.antiviral.2013.05.015, 10.1016/j.antivira1.2013.05.015]
  16. Lenz O, 2015, J HEPATOL, V62, P1008, DOI 10.1016/j.jhep.2014.11.032
  17. Lisboa-Neto G, 2015, ANTIVIR THER, V20, P281, DOI 10.3851/IMP2873
  18. Magiorkinis G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000198
  19. McCloskey RM, 2015, J INFECT DIS, V211, P1288, DOI 10.1093/infdis/jiu613
  20. Nishiya AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086413
  21. Nishiya AS, 2015, BRAZ J INFECT DIS, V19, P473, DOI 10.1016/j.bjid.2015.06.010
  22. Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
  23. Pawlotsky JM, 2014, SEMIN LIVER DIS, V34, P22, DOI 10.1055/s-0034-1371007
  24. Poveda E, 2014, ANTIVIR RES, V108, P181, DOI 10.1016/j.antiviral.2014.05.015
  25. SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
  26. Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
  27. Susser S, 2016, J HEPATOL, V64, pS139, DOI 10.1016/S0168-8278(16)01644-5
  28. Vidal LL, 2016, J VIRAL HEPATITIS, V23, P840, DOI 10.1111/jvh.12503
  29. Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002
  30. Zeuli JD, 2015, DRUG TODAY, V51, P629, DOI 10.1358/dot.2015.51.11.2414528

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/52
Carregar mais